5 tips for people looking to expand their career into climate tech, according to this Houston expert

guest column

A Houston energy professional shares his advice for those looking for a job in climate tech. Photo via Getty Images

If hard times build strong people, then extreme weather events build strong climate tech ecosystems. Nobody knows this conventional wisdom better than Houston.

The past six years alone have seen the second costliest natural disaster in United States history (Hurricane Harvey), the longest power outage in Texas history (Winter Storm Uri), and this June, a heat wave that pushed the ERCOT power grid to record levels.

Combine our ever more volatile climate with a post-COVID-19 reckoning of what it means to work for what you believe in, and you get a recipe for the most significant workforce shift the world has ever seen. This workforce shift rules in favor of climate tech, and it will largely target those who’ve grown up, come of age and started their careers in the midst of this increasing volatility. Climate tech will no longer be considered a standalone industry; it will be baked into all existing industries, and those that don’t accept it will die.

I’m proud to be a climate optimist, but I’m also a realist. The truth is no matter what we do, our volatile climate is going to get worse before it gets better. But if extreme weather events build strong climate tech ecosystems, I can live with that.

To students and young professionals considering a jump into climate tech: There is no better place to be right now. Here are five things to keep in mind as you make that jump.

1. Meet as many people from diverse backgrounds working on as many different things as you can. You will likely feel awkward at first, especially if you don’t naturally gravitate toward conferences and happy hours. At the risk of sounding trite, just treat every stranger like a friend you haven’t met yet. Some of us could probably use more friends anyway.

2. The advice in the self-help book How to Win Friends and Influence People, originally published in 1936, is timeless. Possibly the most useful (and most obvious) point is this: Remember that a person’s name is to that person the sweetest and most important sound in any language. Whenever possible, repeat your new friends’ names when you meet them. Especially if you’re seeking a business development, sales or other external-facing role, perfecting this point should be your Holy Grail.

3. Depending on how new you are to energy and climate tech, you’ll hear lots of unfamiliar lingo. Ask questions, take note of what you still don’t get, and do your best to fill in the gaps on the side. Eventually, acronyms will become your best friend. For example: Have you seen what the ITC and the PTC from the IRA will do to the LCOE of PV according to NREL? IYKYK.

4. Coachability is key. You may feel like you’re getting rejected 99 percent of the time, but the way you respond to and learn from those experiences will ensure the other one percent makes all the difference. At the end of the day, climate tech is so vast that it’s impossible to become an expert in everything, and that’s okay. We may not know what’s going on 70 percent of the time, but I’ll take a .300 batting average any day.

5. It may be impossible to become an expert in everything, but you should proactively learn as much as you can, especially given how quickly the ecosystem is expanding. If you’re not embarrassed by how little you knewone year ago, two years ago or even five years ago, then you’re probably not trying hard enough.

These are only five of my takeaways over the past few years and I’ll be the first to admit that I have a long way to go in implementing them. In a way, that’s what makes this journey what it is. I just can’t wait to see what we build.

---

Ryan Davidson is business development lead for CalWave Power Technologies, a California-based company and Greentown Houston member that's focused on converting ocean waves’ hydrokinetic energy into reliable electricity. This article originally ran on EnergyCapital.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings